Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06878274 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Post-operative Radiotherapy After Neodjuvant Chemo-immunotherapy and Surgery in Stage III NSCLC

Study acronym: RESCUE
StatusRecruiting
PhasePhase 2
Started2026-01-29
View on ClinicalTrials.gov ↗

Amendment history

2026-08-13
Study Status, Sponsor/Collaborators v3
Re-verified, no change to tracked fields
2026-02-07
Study Status, Study Description, Study Design, Eligibility v2
Enrollment target80→118
Eligibility criteriarevised
[...] age III including specifically stage T1-4N2-3 Completion of 32-4 cycles of neoadjuvant chemo-IO, regardless of the specifi [...]
2026-02-05
Not Yet Recruiting→Recruiting Study Identification, Study Status, Oversight, Contacts/Locations v1
Trial statusNot Yet Recruiting→Recruiting
Primary completion date2028-02→2030-02
Completion date2030-02→2032-02
Start dateestimated 2025-05→confirmed 2026-01-29
Study sites0→1
2025-03-11
Original filing
This study investigates whether postoperative radiotherapy (PORT) improves outcomes for patients with stage III non-small cell lung cancer (NSCLC) who have residual disease after neoadjuvant chemo-immunotherapy and surgery. The primary objective is to compare event-free survival (EFS) between patients receiving PORT targeting involved lymph node regions and those without PORT. Secondary and tertiary endpoints include overall survival, locoregional and distant control, toxicity, and quality of life. The phase II randomized trial will enroll 118 patients, stratifying by adjuvant immunotherapy use, with follow-up extending up to 5 years. Statistical analysis aims to detect a 15% improvement in 2-year EFS, with a total study duration of 7 years.
Trial Details
NCT Number NCT06878274
Lead Sponsor Centre hospitalier de l'Université de Montréal (CHUM)
Conditions Non Small Cell Lung Cancer, Stage III Lung Cancer
Enrollment 118 participants
Start Date 2026-01-29
Primary Completion 2030-02 (estimated)
Study Completion 2032-02 (estimated)
Updated on ClinicalTrials.gov 2026-08-14